HEADER PEPTIDE BINDING PROTEIN 09-NOV-20 7AWU TITLE STRUCTURE OF SARS-COV-2 MAIN PROTEASE BOUND TO LSN2463359. COMPND MOL_ID: 1; COMPND 2 MOLECULE: 3C-LIKE PROTEINASE; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: 3CL-PRO,3CLP,MAIN PROTEASE,MPRO,NON-STRUCTURAL PROTEIN 5, COMPND 5 NSP5,SARS CORONAVIRUS MAIN PROTEINASE; COMPND 6 EC: 3.4.22.69; COMPND 7 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS SOURCE 3 2; SOURCE 4 ORGANISM_COMMON: 2019-NCOV, SARS-COV-2; SOURCE 5 ORGANISM_TAXID: 2697049; SOURCE 6 GENE: REP, 1A-1B; SOURCE 7 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 8 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS SARS-COV-2, MPRO, COVID-!9, PEPTIDE BINDING PROTEIN EXPDTA X-RAY DIFFRACTION AUTHOR W.EWERT,S.GUENTHER,P.REINKE,D.OBERTHUER,O.YEFANOV,L.GELISIO,H.GINN, AUTHOR 2 J.LIESKE,M.DOMARACKY,W.BREHM,A.RAHMANI MASHOUR,T.A.WHITE,J.KNOSKA, AUTHOR 3 G.PENA ESPERANZA,F.KOUA,A.TOLSTIKOVA,M.GROESSLER,P.FISCHER, AUTHOR 4 V.HENNICKE,H.FLECKENSTEIN,F.TROST,M.GALCHENKOVA,Y.GEVORKOV,C.LI, AUTHOR 5 S.AWEL,L.X.PAULRAJ,N.ULLAH,S.FALKE,B.ALVES FRANCA,M.SCHWINZER, AUTHOR 6 H.BROGNARO,N.WERNER,M.PERBANDT,H.TIDOW,B.SEYCHELL,T.BECK,S.MEIER, AUTHOR 7 J.J.DOYLE,H.GISELER,D.MELO,I.DUNKEL,T.J.LANE,A.PECK,S.SAOUANE, AUTHOR 8 J.HAKANPAEAE,J.MEYER,H.NOEI,P.GRIBBON,B.ELLINGER,M.KUZIKOV,M.WOLF, AUTHOR 9 L.ZHANG,C.EHRT,J.PLETZER-ZELGERT,J.WOLLENHAUPT,C.FEILER,M.WEISS, AUTHOR 10 E.C.SCHULZ,P.MEHRABI,B.NORTON-BAKER,C.SCHMIDT,K.LORENZEN,R.SCHUBERT, AUTHOR 11 H.HAN,A.CHARI,Y.FERNANDEZ GARCIA,D.TURK,R.HILGENFELD,M.RAREY, AUTHOR 12 A.ZALIANI,H.N.CHAPMAN,A.PEARSON,C.BETZEL,A.MEENTS REVDAT 5 31-JAN-24 7AWU 1 JRNL REVDAT 4 19-MAY-21 7AWU 1 JRNL REVDAT 3 14-APR-21 7AWU 1 COMPND SOURCE JRNL REVDAT 2 09-DEC-20 7AWU 1 JRNL REVDAT 1 02-DEC-20 7AWU 0 JRNL AUTH S.GUNTHER,P.Y.A.REINKE,Y.FERNANDEZ-GARCIA,J.LIESKE,T.J.LANE, JRNL AUTH 2 H.M.GINN,F.H.M.KOUA,C.EHRT,W.EWERT,D.OBERTHUER,O.YEFANOV, JRNL AUTH 3 S.MEIER,K.LORENZEN,B.KRICHEL,J.D.KOPICKI,L.GELISIO,W.BREHM, JRNL AUTH 4 I.DUNKEL,B.SEYCHELL,H.GIESELER,B.NORTON-BAKER, JRNL AUTH 5 B.ESCUDERO-PEREZ,M.DOMARACKY,S.SAOUANE,A.TOLSTIKOVA, JRNL AUTH 6 T.A.WHITE,A.HANLE,M.GROESSLER,H.FLECKENSTEIN,F.TROST, JRNL AUTH 7 M.GALCHENKOVA,Y.GEVORKOV,C.LI,S.AWEL,A.PECK,M.BARTHELMESS, JRNL AUTH 8 F.SCHLUNZEN,P.LOURDU XAVIER,N.WERNER,H.ANDALEEB,N.ULLAH, JRNL AUTH 9 S.FALKE,V.SRINIVASAN,B.A.FRANCA,M.SCHWINZER,H.BROGNARO, JRNL AUTH10 C.ROGERS,D.MELO,J.J.ZAITSEVA-DOYLE,J.KNOSKA, JRNL AUTH11 G.E.PENA-MURILLO,A.R.MASHHOUR,V.HENNICKE,P.FISCHER, JRNL AUTH12 J.HAKANPAA,J.MEYER,P.GRIBBON,B.ELLINGER,M.KUZIKOV,M.WOLF, JRNL AUTH13 A.R.BECCARI,G.BOURENKOV,D.VON STETTEN,G.POMPIDOR,I.BENTO, JRNL AUTH14 S.PANNEERSELVAM,I.KARPICS,T.R.SCHNEIDER,M.M.GARCIA-ALAI, JRNL AUTH15 S.NIEBLING,C.GUNTHER,C.SCHMIDT,R.SCHUBERT,H.HAN,J.BOGER, JRNL AUTH16 D.C.F.MONTEIRO,L.ZHANG,X.SUN,J.PLETZER-ZELGERT, JRNL AUTH17 J.WOLLENHAUPT,C.G.FEILER,M.S.WEISS,E.C.SCHULZ,P.MEHRABI, JRNL AUTH18 K.KARNICAR,A.USENIK,J.LOBODA,H.TIDOW,A.CHARI,R.HILGENFELD, JRNL AUTH19 C.UETRECHT,R.COX,A.ZALIANI,T.BECK,M.RAREY,S.GUNTHER,D.TURK, JRNL AUTH20 W.HINRICHS,H.N.CHAPMAN,A.R.PEARSON,C.BETZEL,A.MEENTS JRNL TITL X-RAY SCREENING IDENTIFIES ACTIVE SITE AND ALLOSTERIC JRNL TITL 2 INHIBITORS OF SARS-COV-2 MAIN PROTEASE. JRNL REF SCIENCE V. 372 642 2021 JRNL REFN ESSN 1095-9203 JRNL PMID 33811162 JRNL DOI 10.1126/SCIENCE.ABF7945 REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH S.GUENTHER,P.Y.A.,REINKE,Y.,FERNANDEZ-GARCIA,J.,LIESKE,T.J., REMARK 1 AUTH 2 LANE,H.M.,GINN,F.H.M.,KOUA,C.,EHRT,W.,EWERT,D.,OBERTHUER,O., REMARK 1 AUTH 3 YEFANOV,S.,MEIER,K.,LORENZEN,B.,KRICHEL,J.D.,KOPICKI,L., REMARK 1 AUTH 4 GELISIO,W.,BREHM,I.,DUNKEL,B.,SEYCHELL,H.,GIESELER,B., REMARK 1 AUTH 5 NORTON-BAKER,B.,ESCUDERO-PEREZ,M.,DOMARACKY,S.,SAOUANE,A., REMARK 1 AUTH 6 TOLSTIKOVA,T.A.,WHITE,A.,HANLE,M.,GROESSLER,H.,FLECKENSTEIN, REMARK 1 AUTH 7 F.,TROST,M.,GALCHENKOVA,Y.,GEVORKOV,C.,LI,S.,AWEL,A.PECK,M., REMARK 1 AUTH 8 BARTHELMESS,F.,SCHLUENZEN,L.X.,PAULRAJ,N.,WERNER,H., REMARK 1 AUTH 9 ANDALEEB,N.,ULLAH,S.,FALKE,V.,SRINIVASAN,B.,FRANCA,M., REMARK 1 AUTH10 SCHWINZER,H.,BROGNARO,C.,ROGERS,D.,MELO,J.J.,DOYLE,J., REMARK 1 AUTH11 KNOSKA,G.E.,PENA MURILLO,A.,RAHMANI MASHHOUR,F.,GUICKING,V., REMARK 1 AUTH12 HENNICKE,P.,FISCHER,J.,HAKANPAEAE,J.,MEYER,P.,GRIBBON,B., REMARK 1 AUTH13 ELLINGER,M.,KUZIKOV,M.,WOLF,G.,BURENKOV,D.,VON STETTEN,G., REMARK 1 AUTH14 POMPIDOR,I.,BENTO,S.,PANNEERSELVAM,I.,KARPICS,T.R., REMARK 1 AUTH15 SCHNEIDER,M.,GARCIA ALAI,S.,NIEBLING,C.,GUENTHER,C.,SCHMIDT, REMARK 1 AUTH16 R.,SCHUBERT,H.,HAN,J.,BOGER,D.,MONTEIRO,L.,ZHANG,X.,SUN,J., REMARK 1 AUTH17 PLETZER-ZELGERT,J.,WOLLENHAUPT,C.,FEILER,M.,WEISS,E.C., REMARK 1 AUTH18 SCHULZ,P.,MEHRABI,K.,KARNICAR,A.,USENIK,J.,LOBODA,H.,TIDOW, REMARK 1 AUTH19 A.,CHARI,R.,HILGENFELD,C.,UETRECHT,R.,COX,A.,ZALIANI,T., REMARK 1 AUTH20 BECK,M.,RAREY,S.,GUENTHER,D.,TURK,W.,HINRICHS,H.N.,CHAPMAN, REMARK 1 AUTH21 A.,PEARSON,C.,BETZEL,A.MEENTS REMARK 1 TITL INHIBITION OF SARS-COV-2 MAIN PROTEASE BY ALLOSTERIC REMARK 1 TITL 2 DRUG-BINDING REMARK 1 REF BIORXIV 2020 REMARK 1 REFN ISSN 2692-8205 REMARK 1 DOI 10.1101/2020.11.12.378422 REMARK 2 REMARK 2 RESOLUTION. 2.07 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : PHENIX 1.18-3855_9999 REMARK 3 AUTHORS : PAUL ADAMS,PAVEL AFONINE,VINCENT CHEN,IAN REMARK 3 : DAVIS,KRESHNA GOPAL,RALF GROSSE-KUNSTLEVE, REMARK 3 : LI-WEI HUNG,ROBERT IMMORMINO,TOM IOERGER, REMARK 3 : AIRLIE MCCOY,ERIK MCKEE,NIGEL MORIARTY, REMARK 3 : REETAL PAI,RANDY READ,JANE RICHARDSON, REMARK 3 : DAVID RICHARDSON,TOD ROMO,JIM SACCHETTINI, REMARK 3 : NICHOLAS SAUTER,JACOB SMITH,LAURENT REMARK 3 : STORONI,TOM TERWILLIGER,PETER ZWART REMARK 3 REMARK 3 REFINEMENT TARGET : GEOSTD + MONOMER LIBRARY + CDL V1.2 REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.07 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 47.74 REMARK 3 MIN(FOBS/SIGMA_FOBS) : 1.420 REMARK 3 COMPLETENESS FOR RANGE (%) : 99.8 REMARK 3 NUMBER OF REFLECTIONS : 15819 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 R VALUE (WORKING + TEST SET) : 0.217 REMARK 3 R VALUE (WORKING SET) : 0.215 REMARK 3 FREE R VALUE : 0.258 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.080 REMARK 3 FREE R VALUE TEST SET COUNT : 803 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (IN BINS). REMARK 3 BIN RESOLUTION RANGE COMPL. NWORK NFREE RWORK RFREE REMARK 3 1 47.7400 - 3.7600 1.00 2564 138 0.1708 0.2216 REMARK 3 2 3.7600 - 2.9900 1.00 2510 120 0.2021 0.2417 REMARK 3 3 2.9800 - 2.6100 1.00 2507 124 0.2413 0.3118 REMARK 3 4 2.6100 - 2.3700 1.00 2491 135 0.2591 0.2765 REMARK 3 5 2.3700 - 2.2000 1.00 2470 144 0.2755 0.3083 REMARK 3 6 2.2000 - 2.0700 1.00 2474 142 0.3075 0.3053 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : FLAT BULK SOLVENT MODEL REMARK 3 SOLVENT RADIUS : 1.11 REMARK 3 SHRINKAGE RADIUS : 0.90 REMARK 3 K_SOL : NULL REMARK 3 B_SOL : NULL REMARK 3 REMARK 3 ERROR ESTIMATES. REMARK 3 COORDINATE ERROR (MAXIMUM-LIKELIHOOD BASED) : 0.276 REMARK 3 PHASE ERROR (DEGREES, MAXIMUM-LIKELIHOOD BASED) : 27.436 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 30.59 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 38.25 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 TWINNING INFORMATION. REMARK 3 FRACTION: NULL REMARK 3 OPERATOR: NULL REMARK 3 REMARK 3 DEVIATIONS FROM IDEAL VALUES. REMARK 3 RMSD COUNT REMARK 3 BOND : 0.006 2475 REMARK 3 ANGLE : 0.700 3367 REMARK 3 CHIRALITY : 0.048 375 REMARK 3 PLANARITY : 0.007 440 REMARK 3 DIHEDRAL : 21.749 899 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : 6 REMARK 3 TLS GROUP : 1 REMARK 3 SELECTION: CHAIN 'A' AND (RESID 1 THROUGH 43 ) REMARK 3 ORIGIN FOR THE GROUP (A): 7.4386 -10.1497 9.4066 REMARK 3 T TENSOR REMARK 3 T11: 0.1976 T22: 0.1672 REMARK 3 T33: 0.2283 T12: -0.0566 REMARK 3 T13: 0.0144 T23: -0.0069 REMARK 3 L TENSOR REMARK 3 L11: 4.5048 L22: 3.0194 REMARK 3 L33: 3.0427 L12: -0.5720 REMARK 3 L13: 2.2457 L23: -0.7853 REMARK 3 S TENSOR REMARK 3 S11: 0.0429 S12: -0.0391 S13: -0.1541 REMARK 3 S21: -0.1051 S22: -0.0281 S23: 0.3219 REMARK 3 S31: 0.1330 S32: -0.1711 S33: -0.0441 REMARK 3 TLS GROUP : 2 REMARK 3 SELECTION: CHAIN 'A' AND (RESID 44 THROUGH 100 ) REMARK 3 ORIGIN FOR THE GROUP (A): 14.1578 -16.2612 20.5697 REMARK 3 T TENSOR REMARK 3 T11: 0.3088 T22: 0.2878 REMARK 3 T33: 0.3512 T12: -0.0196 REMARK 3 T13: 0.0529 T23: 0.0675 REMARK 3 L TENSOR REMARK 3 L11: 3.2173 L22: 5.6810 REMARK 3 L33: 6.0175 L12: 1.1918 REMARK 3 L13: 2.2261 L23: 1.0900 REMARK 3 S TENSOR REMARK 3 S11: 0.2391 S12: -0.5824 S13: -0.3705 REMARK 3 S21: 0.7115 S22: -0.3538 S23: 0.2430 REMARK 3 S31: 0.4130 S32: -0.4629 S33: 0.1048 REMARK 3 TLS GROUP : 3 REMARK 3 SELECTION: CHAIN 'A' AND (RESID 101 THROUGH 155 ) REMARK 3 ORIGIN FOR THE GROUP (A): 9.9829 -2.8006 5.8162 REMARK 3 T TENSOR REMARK 3 T11: 0.2622 T22: 0.1745 REMARK 3 T33: 0.1950 T12: -0.0118 REMARK 3 T13: -0.0238 T23: 0.0416 REMARK 3 L TENSOR REMARK 3 L11: 5.7891 L22: 6.2560 REMARK 3 L33: 2.4525 L12: -0.3292 REMARK 3 L13: 1.3564 L23: -0.0551 REMARK 3 S TENSOR REMARK 3 S11: -0.2376 S12: 0.1277 S13: 0.1506 REMARK 3 S21: -0.5387 S22: 0.0350 S23: 0.0083 REMARK 3 S31: -0.0800 S32: 0.1643 S33: 0.1889 REMARK 3 TLS GROUP : 4 REMARK 3 SELECTION: CHAIN 'A' AND (RESID 156 THROUGH 213 ) REMARK 3 ORIGIN FOR THE GROUP (A): 14.3814 4.0804 7.9894 REMARK 3 T TENSOR REMARK 3 T11: 0.2469 T22: 0.2104 REMARK 3 T33: 0.2362 T12: -0.0523 REMARK 3 T13: 0.0391 T23: 0.0243 REMARK 3 L TENSOR REMARK 3 L11: 1.2975 L22: 3.1023 REMARK 3 L33: 4.0455 L12: -0.7207 REMARK 3 L13: 1.2417 L23: -2.6725 REMARK 3 S TENSOR REMARK 3 S11: -0.1340 S12: -0.0720 S13: 0.1919 REMARK 3 S21: 0.4662 S22: -0.0337 S23: -0.1717 REMARK 3 S31: -0.5412 S32: 0.0521 S33: 0.1741 REMARK 3 TLS GROUP : 5 REMARK 3 SELECTION: CHAIN 'A' AND (RESID 214 THROUGH 274 ) REMARK 3 ORIGIN FOR THE GROUP (A): 15.6221 18.9812 -11.0053 REMARK 3 T TENSOR REMARK 3 T11: 0.3724 T22: 0.2940 REMARK 3 T33: 0.3028 T12: -0.1043 REMARK 3 T13: -0.0210 T23: 0.1250 REMARK 3 L TENSOR REMARK 3 L11: 3.3675 L22: 0.8628 REMARK 3 L33: 4.3597 L12: -0.9715 REMARK 3 L13: -1.0630 L23: 0.7352 REMARK 3 S TENSOR REMARK 3 S11: -0.0171 S12: 0.3552 S13: 0.4636 REMARK 3 S21: -0.1233 S22: -0.0571 S23: -0.1170 REMARK 3 S31: -0.4465 S32: 0.0527 S33: 0.0792 REMARK 3 TLS GROUP : 6 REMARK 3 SELECTION: CHAIN 'A' AND (RESID 275 THROUGH 306 ) REMARK 3 ORIGIN FOR THE GROUP (A): 5.9873 8.8658 -7.5876 REMARK 3 T TENSOR REMARK 3 T11: 0.3622 T22: 0.3916 REMARK 3 T33: 0.2126 T12: -0.1284 REMARK 3 T13: 0.0113 T23: 0.0739 REMARK 3 L TENSOR REMARK 3 L11: 4.1577 L22: 5.7999 REMARK 3 L33: 4.7479 L12: 0.3613 REMARK 3 L13: 0.0423 L23: 3.4861 REMARK 3 S TENSOR REMARK 3 S11: 0.1382 S12: 0.1646 S13: -0.3033 REMARK 3 S21: 0.7025 S22: -0.3399 S23: -0.0256 REMARK 3 S31: 0.6793 S32: -0.6515 S33: 0.1821 REMARK 3 REMARK 3 NCS DETAILS REMARK 3 NUMBER OF NCS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 7AWU COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 11-NOV-20. REMARK 100 THE DEPOSITION ID IS D_1292112236. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 22-APR-20 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 7.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : PETRA III, DESY REMARK 200 BEAMLINE : P11 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.0332 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : PIXEL REMARK 200 DETECTOR MANUFACTURER : DECTRIS PILATUS 6M REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DIALS REMARK 200 DATA SCALING SOFTWARE : DIALS REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 15822 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.070 REMARK 200 RESOLUTION RANGE LOW (A) : 47.740 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.8 REMARK 200 DATA REDUNDANCY : 3.600 REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 4.2900 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.07 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.14 REMARK 200 COMPLETENESS FOR SHELL (%) : NULL REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 1.500 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER REMARK 200 STARTING MODEL: 6YB7 REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 36.10 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 1.92 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: CO-CRYSTALLIZATION WITH THE COMPOUNDS REMARK 280 WAS ACHIEVED BY EQULIBRATING A 6.25 MG/ML PROTEIN SOLUTION IN 20 REMARK 280 MM HEPES BUFFER (PH 7.8) CONTAINING 1 MM DTT, 1MM EDTA, AND 150 REMARK 280 MM NACL AGAINST A RESERVOIR SOLUTION OF 100 MM MIB BUFFER (2:3:3 REMARK 280 MOLAR RATIO OF MALONIC ACID, IMIDAZOLE, AND BORIC ACID), PH 7.5, REMARK 280 CONTAINING 25% V/V PEG 1500 AND 5% V/V DMSO. PRIOR TO REMARK 280 CRYSTALLIZATION COMPOUND SOLUTIONS IN DMSO WERE DRIED ONTO THE REMARK 280 WELLS OF SWISSCI 96-WELL PLATES. TO ACHIEVE REPRODUCIBLE CRYSTAL REMARK 280 GROWTH SEEDING WAS USED. CRYSTALS APPEARED WITHIN A FEW HOURS REMARK 280 AND REACHED THEIR FINAL SIZE AFTER 2 -3 DAYS., COUNTER-DIFFUSION, REMARK 280 TEMPERATURE 291K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: C 1 2 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y,-Z REMARK 290 3555 X+1/2,Y+1/2,Z REMARK 290 4555 -X+1/2,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 3 1.000000 0.000000 0.000000 56.70300 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 26.46450 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 4 -1.000000 0.000000 0.000000 56.70300 REMARK 290 SMTRY2 4 0.000000 1.000000 0.000000 26.46450 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 BIOMT1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 2 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 375 REMARK 375 SPECIAL POSITION REMARK 375 THE FOLLOWING ATOMS ARE FOUND TO BE WITHIN 0.15 ANGSTROMS REMARK 375 OF A SYMMETRY RELATED ATOM AND ARE ASSUMED TO BE ON SPECIAL REMARK 375 POSITIONS. REMARK 375 REMARK 375 ATOM RES CSSEQI REMARK 375 CL CL A 502 LIES ON A SPECIAL POSITION. REMARK 375 HOH A 721 LIES ON A SPECIAL POSITION. REMARK 375 HOH A 744 LIES ON A SPECIAL POSITION. REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 ARG A 222 CG CD NE CZ NH1 NH2 REMARK 470 GLN A 306 CG CD OE1 NE2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASP A 33 -129.14 53.97 REMARK 500 ASN A 51 74.19 -152.00 REMARK 500 ASN A 84 -117.85 54.67 REMARK 500 TYR A 154 -98.84 49.03 REMARK 500 HIS A 164 -56.33 -129.29 REMARK 500 HIS A 164 -58.03 -129.29 REMARK 500 REMARK 500 REMARK: NULL DBREF 7AWU A 1 306 UNP P0DTD1 R1AB_SARS2 3264 3569 SEQRES 1 A 306 SER GLY PHE ARG LYS MET ALA PHE PRO SER GLY LYS VAL SEQRES 2 A 306 GLU GLY CYS MET VAL GLN VAL THR CYS GLY THR THR THR SEQRES 3 A 306 LEU ASN GLY LEU TRP LEU ASP ASP VAL VAL TYR CYS PRO SEQRES 4 A 306 ARG HIS VAL ILE CYS THR SER GLU ASP MET LEU ASN PRO SEQRES 5 A 306 ASN TYR GLU ASP LEU LEU ILE ARG LYS SER ASN HIS ASN SEQRES 6 A 306 PHE LEU VAL GLN ALA GLY ASN VAL GLN LEU ARG VAL ILE SEQRES 7 A 306 GLY HIS SER MET GLN ASN CYS VAL LEU LYS LEU LYS VAL SEQRES 8 A 306 ASP THR ALA ASN PRO LYS THR PRO LYS TYR LYS PHE VAL SEQRES 9 A 306 ARG ILE GLN PRO GLY GLN THR PHE SER VAL LEU ALA CYS SEQRES 10 A 306 TYR ASN GLY SER PRO SER GLY VAL TYR GLN CYS ALA MET SEQRES 11 A 306 ARG PRO ASN PHE THR ILE LYS GLY SER PHE LEU ASN GLY SEQRES 12 A 306 SER CSO GLY SER VAL GLY PHE ASN ILE ASP TYR ASP CYS SEQRES 13 A 306 VAL SER PHE CYS TYR MET HIS HIS MET GLU LEU PRO THR SEQRES 14 A 306 GLY VAL HIS ALA GLY THR ASP LEU GLU GLY ASN PHE TYR SEQRES 15 A 306 GLY PRO PHE VAL ASP ARG GLN THR ALA GLN ALA ALA GLY SEQRES 16 A 306 THR ASP THR THR ILE THR VAL ASN VAL LEU ALA TRP LEU SEQRES 17 A 306 TYR ALA ALA VAL ILE ASN GLY ASP ARG TRP PHE LEU ASN SEQRES 18 A 306 ARG PHE THR THR THR LEU ASN ASP PHE ASN LEU VAL ALA SEQRES 19 A 306 MET LYS TYR ASN TYR GLU PRO LEU THR GLN ASP HIS VAL SEQRES 20 A 306 ASP ILE LEU GLY PRO LEU SER ALA GLN THR GLY ILE ALA SEQRES 21 A 306 VAL LEU ASP MET CYS ALA SER LEU LYS GLU LEU LEU GLN SEQRES 22 A 306 ASN GLY MET ASN GLY ARG THR ILE LEU GLY SER ALA LEU SEQRES 23 A 306 LEU GLU ASP GLU PHE THR PRO PHE ASP VAL VAL ARG GLN SEQRES 24 A 306 CYS SER GLY VAL THR PHE GLN MODRES 7AWU CSO A 145 CYS MODIFIED RESIDUE HET CSO A 145 7 HET S8B A 501 35 HET CL A 502 1 HETNAM CSO S-HYDROXYCYSTEINE HETNAM S8B ~{N}-PROPAN-2-YL-5-(2-PYRIDIN-4-YLETHYNYL)PYRIDINE-2- HETNAM 2 S8B CARBOXAMIDE HETNAM CL CHLORIDE ION FORMUL 1 CSO C3 H7 N O3 S FORMUL 2 S8B C16 H15 N3 O FORMUL 3 CL CL 1- FORMUL 4 HOH *145(H2 O) HELIX 1 AA1 SER A 10 GLY A 15 1 6 HELIX 2 AA2 HIS A 41 CYS A 44 5 4 HELIX 3 AA3 GLU A 47 ASN A 51 5 5 HELIX 4 AA4 ASN A 53 ARG A 60 1 8 HELIX 5 AA5 LYS A 61 HIS A 64 5 4 HELIX 6 AA6 ILE A 200 ASN A 214 1 15 HELIX 7 AA7 THR A 226 TYR A 237 1 12 HELIX 8 AA8 THR A 243 LEU A 250 1 8 HELIX 9 AA9 LEU A 250 GLY A 258 1 9 HELIX 10 AB1 ALA A 260 GLY A 275 1 16 HELIX 11 AB2 THR A 292 GLY A 302 1 11 SHEET 1 AA1 7 VAL A 73 LEU A 75 0 SHEET 2 AA1 7 PHE A 66 ALA A 70 -1 N ALA A 70 O VAL A 73 SHEET 3 AA1 7 MET A 17 CYS A 22 -1 N THR A 21 O LEU A 67 SHEET 4 AA1 7 THR A 25 LEU A 32 -1 O LEU A 27 N VAL A 20 SHEET 5 AA1 7 VAL A 35 PRO A 39 -1 O TYR A 37 N LEU A 30 SHEET 6 AA1 7 VAL A 86 VAL A 91 -1 O LEU A 89 N VAL A 36 SHEET 7 AA1 7 VAL A 77 GLN A 83 -1 N SER A 81 O LYS A 88 SHEET 1 AA2 5 LYS A 100 PHE A 103 0 SHEET 2 AA2 5 CYS A 156 GLU A 166 1 O VAL A 157 N LYS A 100 SHEET 3 AA2 5 VAL A 148 ASP A 153 -1 N ASN A 151 O SER A 158 SHEET 4 AA2 5 THR A 111 TYR A 118 -1 N SER A 113 O PHE A 150 SHEET 5 AA2 5 SER A 121 ALA A 129 -1 O SER A 123 N ALA A 116 SHEET 1 AA3 3 LYS A 100 PHE A 103 0 SHEET 2 AA3 3 CYS A 156 GLU A 166 1 O VAL A 157 N LYS A 100 SHEET 3 AA3 3 HIS A 172 THR A 175 -1 O ALA A 173 N MET A 165 LINK C SER A 144 N CSO A 145 1555 1555 1.33 LINK C CSO A 145 N GLY A 146 1555 1555 1.33 CRYST1 113.406 52.929 44.505 90.00 102.76 90.00 C 1 2 1 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.008818 0.000000 0.001996 0.00000 SCALE2 0.000000 0.018893 0.000000 0.00000 SCALE3 0.000000 0.000000 0.023038 0.00000